# The Biggest Number Is the Weakest

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/the-biggest-number-is-the-weakest

> A prespecified SELECT analysis reports cardiovascular reductions of 26%, 21% and 34% across three definitions of liver fibrosis risk. The 34% is the only one that was not statistically significant.

## Key points

- 26% (P=0.0004) and 21% (P=0.035) reductions held in people with elevated FIB-4.
- The headline 34% was NOT significant (HR 0.66, CI 0.39–1.10, P=0.11). The interval crosses 1.
- Why: strictest criterion → smallest group → fewest events → widest interval.
- FIB-4 is a blood-test screening score, not a fibrosis diagnosis.
- One reported statistic is a hazard ratio for a continuous index change. We print it and do not interpret it.

A prespecified analysis of the SELECT trial asked whether semaglutide still cut cardiovascular events in people whose blood tests suggested liver fibrosis. It reports three answers, for three definitions of high risk: 26%, 21% and 34%.[1] The 34% is the biggest, it is the one that will be quoted, and it is **the only one that was not statistically significant**. Understanding why is more useful than any of the three figures.

## What the analysis did

SELECT enrolled people with overweight or obesity (a BMI of 27 or more) and diagnosed cardiovascular disease, none of whom had diabetes, and gave half of them weekly semaglutide. The drug cut the trial’s combined endpoint (death from cardiac causes, heart attack short of death, or stroke short of death) by a fifth.[2] This analysis takes that population and splits out those at high risk of significant liver fibrosis, using the FIB-4 score.

FIB-4 is a screening calculation from age, platelet count and two liver enzymes. It is not a biopsy and not a scan. “High risk of fibrosis” throughout this analysis means a blood-test score above a threshold, which is a reasonable way to find people worth investigating and is not a diagnosis. Whether blood and imaging tests can stand in for a biopsy is [what one semaglutide trial was built to ask](https://glpwatchdog.org/research/a-trial-about-the-measuring-instrument).

## The three answers

*MACE reduction with semaglutide, by definition of high fibrosis risk.[1]*

| Definition | Reduction | Hazard ratio (95% CI) | P |
| --- | --- | --- | --- |
| FIB-4 ≥ 1.3 | 26% | 0.74 (0.63–0.88) | 0.0004 |
| Age-specific (≥1.3 under 65; ≥2.0 at 65+) | 21% | 0.79 (0.63–0.98) | 0.035 |
| FIB-4 > 2.67, any age | **34%** | **0.66 (0.39–1.10)** | **0.11** |

Look at the third row’s interval. It runs from 0.39 to 1.10. Because 1.10 is above 1, the data are compatible with semaglutide reducing events by 61%, and also compatible with it *increasing* them by 10%. When an interval crosses 1, the result has not distinguished benefit from no effect.

## Why the biggest number is the weakest one

> **This is structural, not bad luck.** The strictest definition of high risk selects the fewest people. The fewest people produce the fewest events. The fewest events produce the widest confidence interval. A wide interval has to be centered somewhere, so it will often land on a striking point estimate that carries almost no information.

That is why ranking these three rows by headline size inverts their ranking by reliability. The 26% figure, with the narrowest interval and a P of 0.0004, is the most trustworthy and the least dramatic. The 34% is the reverse.

> A confidence interval that crosses 1 has not shown an effect, however impressive the number in front of it.

This does not mean the 34% is wrong. The true effect in that group may well be large, and the point estimate is the best single guess available. What it means is that the analysis cannot establish it, and anyone quoting “34% reduction” without the interval is transmitting confidence the data do not contain.

## What the analysis does establish

The two significant rows are the substance. They show that semaglutide’s cardiovascular benefit in SELECT held up in people whose blood work suggested liver fibrosis, at roughly the magnitude seen in the trial overall. Liver risk did not appear to blunt the cardiovascular effect.

That is a modest, useful finding. It is also a subgroup analysis of a trial designed to answer a different question, which is the standing caveat on all such work. Prespecifying the subgroups, as here, is considerably better than choosing the groups after seeing the data, but it does not turn a subgroup into a trial.

> **One reported statistic we are not going to interpret.** The liver measure itself, the fatty liver index, is described as decreasing 28% more with semaglutide, reported as a hazard ratio of 0.72 with a 95% interval of 0.71 to 0.73. A hazard ratio describes time to an event rather than a change in a continuous index, and that interval is far narrower than anything else in the analysis. We report it as published and cannot tell you what form of estimate it is.

## The habit worth taking away

- **Read the interval before the headline.** If it crosses 1 for a ratio, or 0 for a difference, the finding is not established.
- **Be most suspicious of the largest number in a set of subgroups.** It is usually the smallest group.
- **Check whether subgroups were prespecified.** Chosen in advance is a different thing from chosen after looking.
- **Ask what the risk score measures.** Here, “high fibrosis risk” is a blood-test threshold, not a diagnosis.

SELECT turns up across this register in other guises: what the trial says about hospital days, in [days spent in hospital](https://glpwatchdog.org/research/semaglutide-and-days-spent-in-hospital), and how many years of treatment the evidence base covers, in [how long is the evidence](https://glpwatchdog.org/research/how-long-is-the-evidence-actually).

## Frequently asked questions

### Does semaglutide reduce heart events in people with liver fibrosis?

In this prespecified analysis of SELECT, the combined endpoint of cardiac death, heart attack and stroke fell 26% among people whose FIB-4 score reached 1.3 or higher (P = 0.0004) and 21% using an age-specific threshold (P = 0.035). Both are roughly the effect seen in the trial overall.

### What about the 34% reduction?

That figure comes from the strictest definition, a FIB-4 above 2.67, and it was not statistically significant: a hazard ratio of 0.66 with a confidence interval from 0.39 to 1.10, P = 0.11. The interval crosses 1, so the analysis did not distinguish benefit from no effect in that group.

### Why is the biggest reduction the least reliable?

Because the strictest criterion selects the fewest people, who generate the fewest events, which produces the widest confidence interval. A wide interval often lands on a striking point estimate that carries little information.

### Does a FIB-4 score mean someone has liver fibrosis?

No. FIB-4 is a screening calculation from age, platelet count and two liver enzymes. A high score identifies someone worth investigating further; it is not a diagnosis, and no biopsies or scans were involved in defining these groups.

### How much should a subgroup analysis be trusted?

These subgroups were prespecified, which is substantially better than choosing them after seeing the results. It remains a subgroup analysis of a trial powered to answer a different question, so it supports rather than establishes.

## References

1. Meyhöfer SM, Cariou B, Cercato C, et al. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nature Medicine. 2026. PMID: 41928037. https://pubmed.ncbi.nlm.nih.gov/41928037/
2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/

---

Cite as: GLP Watchdog, Nora Bissett, "The Biggest Number Is the Weakest", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/the-biggest-number-is-the-weakest

Canonical HTML page: https://glpwatchdog.org/research/the-biggest-number-is-the-weakest

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
